Thomas Struengmann & family

$10.66B
$65.8M (0.6%)
as of 11/07/24

About Thomas Struengmann & family

Thomas Struengmann and twin brother Andreas were early backers of German firm BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.

The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.

The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.

In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.

Personal stats

Citizenship

Germany

Source of wealth

Pharmaceuticals

Residence

Tegernsee, Germany

Marital status

Married

Birth date

02/16/50 (age 74)

Number of children

4

Education

Master of Business Administration, University of Augsburg; Master of Business Administration, University of Augsburg

Self-made

self-made

Thomas Struengmann & family’s fortune is worth

178K

troy ounces of gold

164K

median U.S. household

107K

median U.S. income

0.213%

U.S. credit card volume

0.043%

GDP of the United States

0.031%

United States debt

Net worth history

Annual ranking

Did you know?

Like his brother, an identical twin, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches.

Net worth over time

Real-time ranking

Financial assets

NASDAQ | BNTX-US

BioNTech Sponsored ADR

undefined | undefined

Formycon

Images © Forbes.com. All rights reserved.